The Effect Of Nab-Paclitaxel On Metastatic Breast Cancer Treatment

Breast cancer is the most common invasive cancer in females worldwide. Metastatic breast cancer(MBC), that is also called stage IV or advanced breast cancer, is breast cancer that has spread frombreast to other organs in the body. Despite advances in early diagnosis, prevention, and treatment,it is still the second-leading cause of cancer-related deaths in women, therefore it is essential toimprove the care of MBC patients, since even today it remains an incurable disease. Taxanes arehighly active chemotherapeutic agents which are used in the treatment of early-stage andmetastatic breast cancer, Docetaxel and paclitaxel are one of the most active agents for thetreatment of breast cancer. These first-generation taxanes are intensely hydrophobic, therefore;solvents are required for its parenteral administration. Nanoparticle albumin-bound paclitaxel(Nab-paclitaxel) technology, that was initially developed more than a decade ago, allows for thetransportation of such hydrophobic drugs with no need of potentially toxic solvents. Nab-paclitaxelcan be administered without premedication, in a shorter infusion time and there is no need for aspecial infusion set. Furthermore, this technology allows the selective delivery of greater amountsof anticancer drug to tumors, by exploiting endogenous albumin pathways and decreasing theincidence of serious toxicities. The aim of this study was to determine the effect of Nab-paclitaxel onmetastatic breast cancer treatment. This article indicated that Nab-paclitaxel can be effective ontreating the metastatic breast cancer.